Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration

Publisher： Karger

E-ISSN： 1423-0267|231|2|80-85

ISSN： 0030-3755

Source： Ophthalmologica, Vol.231, Iss.2, 2013-12, pp. : 80-85

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Review of Ranibizumab Trials for Neovascular Age-Related Macular Degeneration

By Patel Ravi D.   Momi Rominder S.   Hariprasad Seenu M.  

Seminars in Ophthalmology, Vol. 26, Iss. 6, 2011-11 ,pp. : 372-379

Informa Healthcare

Access to resources Recommend Favorite

Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 227, Iss. 1, 2012-04 ,pp. : 11-20

Karger

Access to resources Recommend Favorite

Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 235, Iss. 1, 2016-0 ,pp. : 42-48

Karger

Access to resources Recommend Favorite

Comparison of pro re nata versus Bimonthly Injection of Intravitreal Aflibercept for Typical Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 238, Iss. 1-2, 2017-04 ,pp. : 17-22

Karger

Access to resources Recommend Favorite

Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 223, Iss. 6, 2009-07 ,pp. : 370-375

Karger

Access to resources Recommend Favorite